Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hemodiafiltration

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Hemodiafiltration. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-003479-35 Sponsor Protocol Number: 1 Start Date*: 2006-01-02
    Sponsor Name:Internal Medicine IV, Mecdical University of Vienna
    Full Title: PHARMACOKINETICS OF VORICONAZOLE DURING CONTINUOUS VENOVENOUS HEMODIAFILTRATION
    Medical condition: Intensive Care Patients with proven or suspected infection with fungal pathogens requiring parenteral therapy with voricaonzole who are undergoing continuous venovenous hemodiafiltration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002353-29 Sponsor Protocol Number: HUB-NEF-HEMOCIONA.EC Start Date*: 2019-11-12
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL
    Full Title: PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF APIXABAN IN PATIENTS IN HEMODAFILTRATION
    Medical condition: Chronic kidney disease, non-valvular atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023455-28 Sponsor Protocol Number: 11102010 Start Date*: 2010-12-15
    Sponsor Name:Maija Kaukonen
    Full Title: Dexmedetomidine pharmacokinetics during continuous venovenous hemofiltration and hemodiafiltration in critically ill patients
    Medical condition: Intensive care patients with acute kidney injury requiring continuous renal replacement therapy with a clinical indication for sedation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10069339 Acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019200-23 Sponsor Protocol Number: CMEX839BDE06 Start Date*: 2010-07-01
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A multi-center, prospective, open-label, 8-weeks study to investigate the efficacy, safety and pharmacokinetics of certoparin (3000 IU anti-Xa bolus, with the option to titrate dose) in the prophyl...
    Medical condition: patients undergoing chronic dialysis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066622 Chronic hemodialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-018010-18 Sponsor Protocol Number: V1.0,29.11.2009 Start Date*: 2010-07-02
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I,Abt. f. Infektionen u.Tropenmedizin
    Full Title: Multiple-dose Pharmacokinetics of Doripenem during continuous venovenous hemodiafiltration and molecular adsorbent recirculating system in ICU patients and during hemodialysis in longterm hemodialy...
    Medical condition: pharmacokinetics of Doripenem during CVVHDF(intensive care patients continuous venovenous haemodiafiltration), MARS(extracorporeal liver assist device, using a hollow fiber dialysis column in which...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005617-39 Sponsor Protocol Number: WS2030571 Start Date*: 2014-01-14
    Sponsor Name:University Hospital Tuebingen
    Full Title: Pharmacokinetics of Tigecycline in Patients Receiving Continuous Renal Replacement Therapy
    Medical condition: Surgical ICU patients with severe infection and renal replacement therapy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000421-31 Sponsor Protocol Number: Etelcalcetide-T50-CKD5D-2018 Start Date*: 2018-12-19
    Sponsor Name:Ordensklinikum Linz GmbH, ELISABETHINEN, Interne 3
    Full Title: A study to investigate the influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients
    Medical condition: End stage renal disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004789-24 Sponsor Protocol Number: PA21-T50-CKD5D-2016 Start Date*: 2017-03-10
    Sponsor Name:Ordensklinikum Linz, Krankenhaus der Elisabethinen Linz GmbH, III. Interne
    Full Title: The Effect of Phosphate Lowering using sucroferric oxyhydroxide (PA21) on Calcification Propensity of Serum – a randomized, controlled, open-label, cross-over trial
    Medical condition: end stage renal disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003029-14 Sponsor Protocol Number: D9480C00006 Start Date*: 2018-02-09
    Sponsor Name:AstraZeneca AB
    Full Title: A phase 3b, multicenter, prospective, randomized, double blind, placebocontrolled study to reduce incidence of pre-dialysis hyperkalemia with Sodium Zirconium Cyclosilicate (DIALIZE)
    Medical condition: Hyperkalemia among patients on stable hemodialysis (pre-dialysis serum K >5.4 mmol/L after long inter-dialytic interval and >5.0 mmol/L after one short inter-dialytic interval)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020646 Hyperkalaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004426-24 Sponsor Protocol Number: 951/07 Start Date*: 2007-07-06
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PROSTACYCLIJN VERSUS HEPARIN AS ANTICOAGULANT IN CONTINUOUS VENO-VENOUS HEMODIAFILTRATION
    Medical condition: Acute renale failure in intensive unit
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038436 Renal failure acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002069-11 Sponsor Protocol Number: 1 Start Date*: 2008-09-10
    Sponsor Name:Medizinische Universität Wien, Univ. Klinik für Innere Medizin III, Abteilung für Gastroenterologie
    Full Title: PHARMACOKINETICS OF GANCICLOVIR DURING CONTINUOUS RENAL REPLACEMENT THERAPY
    Medical condition: Medical Intensive Care Unit Renal failure Renal Replacement Therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038435 Renal failure LLT
    9.1 10011827 Cytomegaloviral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004794-33 Sponsor Protocol Number: PA101B-UP-02 Start Date*: 2016-03-25
    Sponsor Name:Patara Pharma, LLC
    Full Title: Treatment of Uremic Pruritus with Inhaled PA101B in Patients with End-Stage Renal Disease Requiring Hemodialysis
    Medical condition: Uremic Pruritus in patients with end-stage renal disease requiring hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10060884 Uremic pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006772-30 Sponsor Protocol Number: 20-026 Start Date*: 2009-03-10
    Sponsor Name:Medical University of Graz
    Full Title: Evaluation of HCV clearance by hemodialysis
    Medical condition: Chronic hepatitis C in patients with chronic renal failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10066622 Chronic hemodialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001809-14 Sponsor Protocol Number: E2015-PK-HD-PTAZ-MERO-CTAZ Start Date*: 2015-06-24
    Sponsor Name:Hopital Erasme
    Full Title: Beta-Lactams (ceftazidime, piperacilline-tazobactam, meropenem) dosing scheme validation in septic hemodialysed patient
    Medical condition: sepsis in patient undergoing dialysis for renal insufficiency
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10040054 Sepsis, bacteraemia, viraemia and fungaemia NEC HLT
    18.0 100000004869 10012347 Dependence on renal dialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006097-15 Sponsor Protocol Number: CSBR759A2304 Start Date*: 2009-05-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, placebo-controlled multi-center trial to compare the phosphate lowering efficacy of different doses of SBR759 to placebo
    Medical condition: hyperphosphataemia in chronic kidney disease patients on renal replacement therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) BE (Completed) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004790-32 Sponsor Protocol Number: 204836 Start Date*: 2016-03-07
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A 29-day, randomized, double-blinded, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of GSK1278863 in hemo...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10002272 Anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003140-71 Sponsor Protocol Number: RMFPC-22 Start Date*: 2020-08-25
    Sponsor Name:Rockwell Medical, Inc.
    Full Title: Hemoglobin maintenance in pediatric ESRD patients by ferric pyrophosphate citrate (FPC)
    Medical condition: Iron deficiency anaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005561-14 Sponsor Protocol Number: D9487C00001 Start Date*: 2021-07-15
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic...
    Medical condition: Pre-dialysis hyperkalemia in patients with end stage renal disease (ESRD) on chronic hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10020646 Hyperkalaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003957-27 Sponsor Protocol Number: 20115 Start Date*: 2020-07-15
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, parallel group, placebo-controlled, multi-center study to assess the safety and tolerability of monthly subcutaneous administrations of a low and high dose cohort of oso...
    Medical condition: Prevention of thromboembolic events in ESRD patients on hemodialysis who are at risk for thromboembolic events
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10049910 Thromboembolism prophylaxis LLT
    21.1 100000004865 10066622 Chronic hemodialysis LLT
    21.0 10038359 - Renal and urinary disorders 10077512 End stage renal disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) GR (Completed) BE (Completed) PT (Completed) NL (Completed) LT (Completed) PL (Completed) HU (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004608-21 Sponsor Protocol Number: 20170724 Start Date*: 2019-07-30
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of age With Secondary Hyperp...
    Medical condition: Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) HU (Completed) FR (Completed) PL (Trial now transitioned) LT (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:51:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA